Aurobindo Pharma Surges 8.4% Revenue, Europe Leads Growth

OTHER
Whalesbook Logo
AuthorIshaan Verma|Published at:
Aurobindo Pharma Surges 8.4% Revenue, Europe Leads Growth
Overview

Aurobindo Pharma reported an 8.4% YoY revenue increase to ₹8,646 crores for Q3 FY26, fueled by a robust 27.4% surge in Europe and stable US performance. EBITDA grew 9.0% to ₹1,773 crores, with margins holding steady at 20.5%. The company highlighted progress in its biosimilars pipeline and secured product approvals in the US, while maintaining a healthy net cash position.

📉 The Financial Deep Dive

The Numbers:

Aurobindo Pharma Limited announced its unaudited financial results for Q3 FY26, reporting consolidated revenue from operations of ₹8,646 crores, an 8.4% increase year-on-year (YoY). Quarter-on-quarter (QoQ), revenue grew by 4.3% from ₹8,286 crores. EBITDA for the quarter stood at ₹1,773 crores, up 9.0% YoY. The EBITDA margin improved slightly to 20.5% from 20.4% in the prior-year quarter, driven by stable gross margins and operating efficiencies. Net Profit attributable to owners was ₹910 crores, a 7.6% YoY increase, with Earnings Per Share (EPS) rising 7.7% YoY to ₹15.67.

The Quality:

Gross profit surged by 10.8% YoY to ₹5,165 crores, with gross margins expanding 130 basis points to 59.7%. Despite an 11.7% YoY increase in overheads, strong revenue and gross margin performance translated to improved operating profitability. The company generated US$118 million in free cash flow during the quarter. Aurobindo maintained a strong net cash position of approximately ₹2,583 crores (US$287 million) as of December 2025, following cash appropriation for the Khandelwal Labs acquisition.

The Grill:

While the results were largely positive, the API segment posted revenues of ₹963 crores, a 4.3% YoY decline, attributed to market conditions. Furthermore, the company noted that the timeline for the Denosumab filing has been delayed due to extended validation requirements. These points represent areas for investor vigilance regarding market pressures and execution timelines.

Risks & Outlook:

Key priorities for Aurobindo Pharma include accelerating product launches in Europe, expanding into growth markets, and optimizing its product portfolio. The strategic focus on biosimilars, with a pipeline of 15 products, positions the company for future growth through 2030. Clinical comparability has been achieved for Denosumab (BP16) and Omalizumab (BP11) candidates, with filings planned in the EU and US in CY2026. Growth markets like LATAM are also being targeted for expansion. The company maintained a healthy R&D expenditure of ₹409 crores (4.7% of sales), primarily directed towards biosimilars and specialty product development.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.